Results 71 to 80 of about 125,001 (364)

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

New England Journal of Medicine, 2013
BACKGROUND Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone ...
Klopidogrel S Aspirinem, naopak nezpůsobila, vyšší výskyt, hemorhagických komplikací, než léčba, Yongjun Wang, Yilong Wang, Chunxue Wang, L. Cui, J. Zeng, S. Mekaru   +10 more
semanticscholar   +1 more source

Clopidogrel for the Hot Patient [PDF]

Circulation: Cardiovascular Interventions, 2009
Inflammation plays a critical role in the initiation, progression, and clinical complications of atherosclerosis.1 Experimental evidence indicates that lesion formation is dependent on heterotypic interactions among immune cells, endothelial cells, and platelets.
Daniel I. Simon, Matthew L. Bilodeau
openaire   +3 more sources

Investigation of Genomic and Transcriptomic Risk Factors of Clopidogrel Response in African Americans. [PDF]

Clin Pharmacol Ther
Clopidogrel, an anti‐platelet drug, is used to prevent thrombosis after percutaneous coronary intervention. Clopidogrel resistance results in recurring ischemic events, with African Americans (AA) suffering disproportionately. The aim of this study was to discover novel biomarkers of clopidogrel resistance in African Americans using genome and ...
Yang G, Alarcon C, Chanfreau C, Lee NH, Friedman P, Nutescu E, Tuck M, O'Brien T, Gong L, Klein TE, Chang KM, Tsao PS, Meltzer DO, Lynch JA, Million Veteran Program, Tuteja S, Perera MA.   +16 more
europepmc   +2 more sources

Priority setting for research in health care: An application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome [PDF]

, 2006
The purpose of this study is to explain the rationale for the value of information approach to priority setting for research and to describe the methods intuitively for those familiar with basic decision analytical modeling.
Bojke, L., Claxton, K., Palmer, S., Philips, Z., Sculpher, M.   +4 more
core   +1 more source

Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate

Brazilian Journal of Cardiovascular Surgery
Introduction: Antiplatelet therapy after coronary artery bypass graft (CABG) has been used. Little is known about the predictors and efficacy of clopidogrel in this scenario. Objective: Identify predictors of clopidogrel following CABG.
Paulo Roberto L. Prates, Judson B. Williams, Rajendra H. Mehta, Susanna R. Stevens, Laine Thomas, Peter K. Smith, L. Kristin Newby, Renato A. K. Kalil, John H. Alexander, Renato D. Lopes   +9 more
doaj   +1 more source

Clopidogrel in Orthopaedic patients: a review of current practice in Scotland

Thrombosis Journal, 2007
Background Clopidogrel bisulfate is an antiplatelet agent used to prevent ischaemic events in patients with vascular disease. Current guidelines recommend withholding clopidogrel for 7 days pre-operatively.
Bramley Diane, Pillai Anand, Joseph Jibu J   +2 more
doaj   +1 more source

Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

JAMA Internal Medicine, 2020
Importance Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased ...
R. Turgeon, S. Koshman, E. Youngson, B. Har, S. Wilton, M. James, M. Graham   +6 more
semanticscholar   +1 more source

Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]

, 2019
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A, Gue, Ying X, Kanji, Rahim, Srinivasan, Manivannan, Wellsted, David M, Wyatt, Solange   +5 more
core   +1 more source

Genetic determinants of response to clopidogrel and cardiovascular events.

New England Journal of Medicine, 2009
BACKGROUND Pharmacogenetic determinants of the response of patients to clopidogrel contribute to variability in the biologic antiplatelet activity of the drug.
T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, N. Meneveau, P. Steg, J. Ferrières, N. Danchin, L. Becquemont, Abstr Act   +10 more
semanticscholar   +1 more source

Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome

Circulation, 2020
Supplemental Digital Content is available in the text. Background: The comparative efficacy and safety of ticagrelor versus clopidogrel in older patients with myocardial infarction (MI) has received limited study.
K. Szummer, M. Montez-Rath, J. Alfredsson, D. Erlinge, B. Lindahl, R. Hofmann, A. Ravn-Fischer, P. Svensson, T. Jernberg   +8 more
semanticscholar   +1 more source